Health reporter
Getty imagesTreatment should be more individual for millions of people with type 2 diabetes, with high access to new drugs, including weight -loss drugs, Healthcare assessment bodies for England, Wales and North Ireland have recommended.
It takes the “biggest shake-up” step in Type 2 Diabetes Care in a decade.
The National Institute for Health and Care Excellence (NICE) says that offering new drugs to more people will prevent complications such as heart disease, stroke and kidney damage and potentially saved life.
About 4.6 million people in the UK are diagnosed with diabetes – these 90% have type 2, with no possibility of another 1.3 million.
Type 2 diabetes means that there is too much glucose or sugar in the blood. It gives great risk to stroke, heart attack, heart failure and other health conditions. Now it is so common that 10% of the NHS budget goes towards treating it.
Nice, which produces guidance to NHS, recommends the best care to patients, a “one size fits all” approaches and recommends a step towards more individual treatment.
It is calling for new diabetes drugs called SGLT-2 inhibitors, which to protect the heart and kidney as well as to reduce blood sugar levels, to become the first choice treatment for all diabetic patients. About 2.3 million people will be eligible for these drugs.
Some 22,000 people can be saved if 90% of all diabetic patients were determined, called NIS, but access is not the same in Britain. There is evidence that women, old people and black people are less likely to be determined.
Chairman of the Guidelines Committee, Dr. Waqar Shah said, “There is some urge to find ways to increase the upliftment of SGLT-2 inhibitors because if we receive the right umptake, the nation will be very healthy,” the Chairman of the Guidelines Committee, Dr. Waqar Shah said.
Out of five people with type 2 diabetes and heart disease, only one present drugs are prescribed.
More people will benefit the people living in poor areas and ethnic minorities to determine bullets, called Nice.
Under guidanceWhich is still in a draft phase and needs to undergo a consultation, about 750,000 more people with type 2 diabetes GLP-1 agonist such as semaglutide and liraglutide will be offered, which have become very popular as drugs contained in weight loss jab.
Adults with heart disease and some that develop type 2 are groups before 40 are recommended to be introduced to them.
These drugs can be used to reduce both blood sugar levels and support some weight loss.
Deputy Chief Executive Officer and Chief Medical Officer Prof. Jonathan Benagar at NICE said that updated guidance was “a significant development” in type 2 diabetes treatment that can help prevent heart attacks, strokes and other serious complications before it is.
He said, “This guidance means that more people will be offered medicines, where it is right to do, to reduce their future sick health risk,” he said.
Guidelines are part of a long -term plan to focus on reducing health inequalities by NHS in England and focusing on preventing sick health in the first place.
Charity Diabetes UK said that the announcement made type 2 diabetes treatment “in the 21st century”.
Douglas Twainfor, head of the clinical in charity, said, “These guidelines can take a long way to help address the inequalities in type 2 diabetes treatment and results, along with reducing the burden of living with this tireless situation.”
